Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · IEX Real-Time Price · USD
13.89
-0.23 (-1.63%)
At close: Jul 2, 2024, 4:00 PM
13.35
-0.54 (-3.89%)
After-hours: Jul 2, 2024, 5:49 PM EDT
Company Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy.
The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Avadel Pharmaceuticals plc
| Country | Ireland |
| IPO Date | Jun 7, 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 154 |
| CEO | Gregory J. Divis Jr. |
Contact Details
Address: Block 10-1 Blanchardstown Corporate Park, Ballycoolin Dublin, L2 15 Ireland | |
| Phone | 636-449-1830 |
| Website | avadel.com |
Stock Details
| Ticker Symbol | AVDL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001012477 |
| CUSIP Number | 05337M104 |
| ISIN Number | US05337M1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory J. Divis Jr. | Chief Executive Officer and Director |
| Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer and Chief Financial Officer |
| Richard J. Kim | Chief Commercial Officer |
| Jerad G. Seurer | General Counsel and Company Secretary |
| Gregory J. Davis | Vice President of Corporate and Business Development |
| Mark W. Elrod | Vice President of Sales |
| Angie Woods | Vice President of People and Culture |
| Dr. Jordan S. Dubow M.D. | Consultant |
| Dr. Jason M. Vaughn | Senior Vice President of Technical Operations |
| Jennifer Gudeman PharmD | Senior Vice President of Medical and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | 8-K | Current Report |
| Jun 18, 2024 | ARS | Filing |
| Jun 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 18, 2024 | DEF 14A | Other definitive proxy statements |
| May 21, 2024 | 8-K | Current Report |
| May 17, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 8, 2024 | 8-K | Current Report |
| May 8, 2024 | 424B5 | Filing |
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |